[go: up one dir, main page]

EP1044214A1 - Procede de liaison d'albumine et systeme destine a etre utilise dans ledit procede - Google Patents

Procede de liaison d'albumine et systeme destine a etre utilise dans ledit procede

Info

Publication number
EP1044214A1
EP1044214A1 EP98965360A EP98965360A EP1044214A1 EP 1044214 A1 EP1044214 A1 EP 1044214A1 EP 98965360 A EP98965360 A EP 98965360A EP 98965360 A EP98965360 A EP 98965360A EP 1044214 A1 EP1044214 A1 EP 1044214A1
Authority
EP
European Patent Office
Prior art keywords
group
anyone
albumin
binding
conjugated partner
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98965360A
Other languages
German (de)
English (en)
Inventor
Ake Pilotti
Tor Regberg
Christel ELLSTRÖM
Charlotta Lindqvist
Ann Eckersten
Lars FÄGERSTAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytiva Sweden AB
Original Assignee
Amersham Pharmacia Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/001,940 external-priority patent/US5994507A/en
Priority claimed from SE9800879A external-priority patent/SE9800879D0/xx
Application filed by Amersham Pharmacia Biotech AB filed Critical Amersham Pharmacia Biotech AB
Publication of EP1044214A1 publication Critical patent/EP1044214A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Definitions

  • This invention concerns the use of a compound that is able to bind to albumin.
  • Albumin-binding ligands attached to a solid phase have been used for the removal of albumin from liquid samples mainly for two purposes: a) purification of albumin and b) further processing of the liquid samples in the absence of albumin.
  • the step involving binding to an albumin ligand has often been combined with other steps including ion exchange and binding based on hydrophobic interaction. Both batch-wise and chromatographic processes have been described.
  • Albumin-binding ligands in soluble form have been used for desorption of albumin adsorbed to a matrix via an albumin- binding ligand (e.g. regeneration of adsorbents).
  • the present invention aims at providing solutions to these demands and needs .
  • a first aspect of the invention provides a method for binding albumin by contacting an aqueous liquid containing an albumin with an albumin binding compound which comprises the structure (scaffold)
  • binding is unknown, but it is believed that ionic, hydrophobic, dipole-dipole interactions and other interactions of non-covalent nature may be involved including also hydrogen bonds and a good geometric fitness between the compound and the binding site on an albumin molecule. This type of ability to bind will be referred to as affinity.
  • the scaffold may be part of a conjugate or a free compound.
  • the use may be expressed as a method for binding albumin to an albumin-binding compound wherein the compound is selected from albumin-binding compounds containing the scaffold I.
  • a second aspect of the invention is novel conjugates that exhibit the scaffold I activity where the substituents at the free valences in formula I are combined in a novel manner so as to optimize binding via affinity to an albumin.
  • albumin is typically contemplated serum albumins from mammals and proteins having the analogous function in other vertebrates.
  • the term albumin also encompasses albumin variants, such as genetically engineered forms, mutated forms, and fragments etc. having one or more binding sites that are analogous to a binding site unique for one or more vertebrate albumins as defined above.
  • analogous binding sites in the context of the invention are contemplated structures that are able to compete with each other for binding to one and the same ligand structure.
  • albumins also encompasses lactalbumin, ovalbumin etc.
  • a low molecular weight (Mw) compound binding to one or more single binding sites on an albumin molecule through affinity will further on be called an albumin-binding ligand, or simply ligand.
  • An albumin- binding ligand covalently attached to a carrier molecule gives an albumin-binding ligand-carrier conjugate, or simply a ligand-carrier conjugate or conjugate.
  • the carrier molecule may also be called conjugated partner.
  • Conjugates may contain one or more ligand structures binding to albumin.
  • the Mw of the carrier is as a rule larger than the Mw of the scaffold I, i.e. larger than 96 dalton.
  • albumin binders is used generically to encompass albumin-binding ligands, albumin-binding ligand- carrier conjugates and other compounds exerting affinity to albumin.
  • m is zero or 1. represents that the conjugated partner is replacing a hydrogen in A, B, or -L-G.
  • This aspect of the invention may be used for the removal or purification of albumin from a liquid sample.
  • a liquid sample containing albumin is contacted with a conjugate according to formula II in which m is equal to 1 and the conjugated partner is a carrier (matrix) that is soluble, insoluble or insolubilizable in aqueous liquid media.
  • the matrix with bound albumin is separated from the liquid in a subsequent step and the bound albumin released, collected and further processed using methods that are known in the art.
  • the binding step is called adsorption and the release step desorption.
  • the conditions (pH, ionic strength, temperature, etc.) for adsorbing/desorbing should be non- denaturing for albumin with respect to irreversible denaturation in particular.
  • Soluble carriers may be insolubilized after the binding step in order to facilitate physical separation of the complex between albumin and the ligand-carrier conjugate from the medium. Insolubilization steps typically take place before any release step.
  • a subaspect of the present invention is a method of obtaining samples that are free of one or more of the albumins mentioned above, for instance for the purification of compounds other than the typical albumins as defined above. Release and washing steps may be included as in conventional purification of albumins in order to be able to reuse the ligand-carrier material.
  • Removal of albumin according to the first aspect of the invention may be part of a chromatographic process utilizing as the conjugated partner an insoluble carrier in the form of a monolith or a population of particles/beads onto which surfaces an inventive albumin binder has been immobilized.
  • Particles/beads may be in the form of a packed or fluidised bed. Fluidised beds may be stably expanded allowing chromatographic processes to take place.
  • Particulate carriers may alternatively be used in batch-wise processes involving e.g. stirred suspensions.
  • the aromatic rings may typically comprise one, two or three heteroatoms providing at least one free electron pair and are selected from among oxygen, nitrogen or sulphur.
  • the aromatic rings may be fused to other aromatic or non-aromatic rings each of which may have heteroatoms as discussed above.
  • the two groups containing the aromatic rings are represented by parts A and B. These parts are often interchangeable .
  • the 5- or 6-membered aromatic ring may be represented by the formula:
  • the link from the aromatic ring to the scaffold I is through replacement of a hydrogen in D or of one of Ri and R 2 , or one of R 3 and R 4 .
  • a link to the scaffold I through replacement of one of R 3 and R 4 is only possible provided that R 3 and R 4 do not define a bivalent structure that is part of a ring fused to the aromatic ring of formula III.
  • These structural units may be inserted in either direction in formula III.
  • the aromatic ring systems defined by formula III include phenyls, 1- and 2-naphthyls, 1- and 2-thienyls, 2-, 3- and 4-pyridyls, 2-, 3- and 4-quinolyls, 1-, 3- and 4- isoquinolyls, 2- and 3-indolyls, 2- and 3-furanyls, 1-, 2- and 3-pyrrolyls etc.
  • Ri and R 2 may be selected from: a. hydrogen (no replacement), alkyl, aryl, alkoxy, aryloxy and their thio analogues, typically a C]__]_g alkyl or 05-15 aryl groups optionally substituted with one or more halo groups, e.g. CF3-, CH3-, phenyl etc; b. halo, such as fluoro or chloro or bromo; c. nitro; d. cyano, carboxamido (-CONH2) and carboxy (-COOH) .
  • Groups such as N-substituted carboxamido (-CONH2) with one or two amino hydrogens replaced with hydrocarbyl and hydrocarbyl esters and salts of carboxy, are included in carboxamido and carboxy, respectively.
  • Typical hydrocarbyls are C]__]_Q alkyl, such as arylalkyl or unsubstituted alkyl, or alkylaryl or unsubstituted aryl, for instance containing 5-15 carbons.
  • Aryl groups may include phenyl, 1- and 2- naphthyls, 1-, 2- or 3-pyridyls etc. e.
  • alkylated and acylated forms are those which are substituted with 1, 2 or 3 lower alkyls (Ci-12) or lower acyls (Ci-13), typically methyl or acetyl, respectively.
  • the albumin-binding activity also possibly may be at hand for other R 3 and R 4 than those specified here, for instance groups specified in a-e above. Normal valence rules apply
  • L is an organic structure and may be - ⁇ (CH2) n ( )m' ( H2)n' _ where the left and right free valences bind to the right carbonyl group of the scaffold and to the group G, respectively.
  • X may be oxygen, sulphur or NH with the hydrogen preferably being replaced with a methyl group or a C2-10 alkyl.
  • n and n 1 are integers 0-3 and m' is an integer 0 or 1 with the proviso that n+n'+m 1 is 1, 2 or 3.
  • One or more of the hydrogen atoms in a CH2 _ group of the linker may be replaced with a C]__ ⁇ o alkyl group, or a hydroxy, a carboxy or an amino group or any other group containing a functional group enabling further derivatization and linking to a carrier .
  • albumin binders in which X is NH with the hydrogen being replaced as suggested in the preceding paragraph and/or one or more of the CH2 ⁇ groups being substituted with a methyl and/or some other group as suggested in the preceding paragraph.
  • a preferred linker chain of the invention has substituents on the linker L so that rotation around bonds in the linker chain is hindered. Other means for hindering rotation in this part of the molecule may have similar effects on the affinity for albumin, for instance divalent groups bridging a position in L-G with a position in A or B or in the scaffold.
  • G is typically a hydrophobic group, such as a straight, branched or cyclic hydrocarbyl which possibly is substituted with, for instance, halo or hydroxy groups, etc.
  • G may be an aromatic group, such as phenyl, that may be substituted with a hydroxy and/or C]__]_Q alkyl (e.g. methyl) in the ortho, meta or para position relative to the ring position binding to L.
  • m is 1.
  • the conjugated partner is linked to an albumin-binding ligand as defined in formula II via a bridge.
  • the bridge may derive wholly or partly from the ligand or from the conjugated partner. For the sake of simplicity the bridge will be discussed as an inherent part of the conjugated partner, unless otherwise specified.
  • the conjugated partner itself may comprise additional albumin-binding ligands of the same or different structure as the ligand shown in formula II.
  • the conjugated partner may be attached to the ligand at a position in group A, B or L-G. It is preferred to have the conjugated partner attached (a) at a functional group in the linker L as suggested above, or
  • the bridge may thus have: -CH 2 -CH 2 -, -CH 2 NH-, -NHCH 2 -, -CH 2 S-, -SCH 2 -, -CH 2 0-, or - OCH 2 - next to the aromatic ring of part A or B.
  • conjugate in organic chemistry and biochemistry is well known and encompasses two or more compounds which are linked together covalently so that properties from each compound are retained in the conjugate.
  • conjugate means that an albumin-binding ligand as defined in formula II
  • conjugated partner is covalently linked (conjugated) to a compound (conjugated partner) that has a property that is retained in the conjugate.
  • the conjugated partner may render the conjugate soluble, insoluble or insolubilizable in the media concerned, analytically detectable, reactive against a specified target such as a biospecific counterpart etc.
  • the conjugated partner (carrier) may be insoluble, insolubilizable or soluble in the liquid media concerned.
  • Typical media are aqueous, including water possibly containing water-miscible organic liquids, and other liquid media in which binding to albumin may take place.
  • Typical carriers are based on organic or inorganic polymers which may be of synthetic or biological origin (biopolymers) .
  • Insoluble carriers may be of the same kind as the carriers used as support in chromatography . Suitable insoluble carriers may be of various physical forms such as monoliths, particles, tube walls etc. The carriers may be porous or non-porous .
  • the carrier may contain density controlling filler material (particles) embedded in a polymer.
  • density controlling filler material particles embedded in a polymer.
  • Well known hydrophilic organic insoluble carriers are polymers which have on their liquid contact surface a plurality of hydrophilic groups, for instance hydroxy and/or amino and/or carboxy.
  • hydrophobic carriers that have been hydrophilized (e.g. coated with a hydrophilic compound) on outer and inner (pore) surfaces.
  • Typical hydrophobic insoluble carriers are based on styrene-divinyl-benzene polymer ' s, poly (alkyl methacrylates), polymers of perfluoro hydrocarbons (PFC) etc.
  • Inorganic variants of carriers may be based on materials such as glass, zeolites, silica, composites, zirconium oxide, etc.
  • Typical examples of carriers that are soluble in aqueous media as defined above are water soluble polymers, such as dextran.
  • the conjugated partner may contain an analytically detectable label, such as an enzymatically active moiety, a fluorophor/fluorogen and a chromophor/chromogen etc. a moiety giving the conjugate a predetermined reactivity, such as biotin, or a chemically reactive group.
  • Analytically detectable conjugates may be useful in an assay such as immunoassay methods.
  • Conjugates with a predetermined reactivity such as biotin or a chemically reactive group will allow introduction of albumin-binding structures containing the scaffold I onto various types of other carriers, for instance for use in the above-mentioned methods for removal of albumin.
  • a predetermined reactivity such as biotin or a chemically reactive group
  • conjugated partners normally result in soluble conjugates.
  • Compounds of formula II may or may not bind to albumin.
  • albumin-binding experiments as outlined in the examples below are particularly useful. This screening method has enabled quick screening and optimization of compounds containing the inventive albumin-binding scaffold.
  • albumin affinity compounds have been found.
  • any known method for checking affinity between two compounds may be modified and applied to screen for albumin- binding ligands. See for instance WO-A-9622530.
  • the conjugate of the second aspect of the invention has the formula (II):
  • the conjugated partner is a polymeric carrier.
  • the conjugated partner is linked to the ligand either at the A- or B-part or at L.
  • the preferred variants are those that are preferred for use in the first aspect of the invention.
  • a third aspect of the invention are new albumin binders having been obtained by changing one or more structural elements of the structure of an albumin binder complying with formula I, in particularly with formula II. This can be accomplished, for instance, by creating and screening chemical libraries in which the members differ around one structural elements of an albumin binder complying with formula I, in particular formula II. Structural elements to be changed may be the scaffold I, or part A, part B or L-G of the presently claimed albumin binders. Typically at least one of these elements is retained in an albumin binder according to this aspect of the invention.
  • a chemical library is contemplated a collection (an array) of two, three or more structurally different compounds.
  • the procedure comprises the steps:
  • the ligand to be assayed was dissolved in PBS and mixed with HSA (100 mM HSA in PBS) .
  • the volume of the solution was selected so that the ratio between the ligand and HSA was 5:1 with final concentrations were for ligand 50 ⁇ M in 10 ⁇ M HSA (human serum albumin) .
  • the free ligand not bound to HSA was then removed by rapid passage through a HITRAP desalting column (SEPHADEX G25; Pharmacia Biotech AB, Uppsala, Sweden) .
  • the void fraction from the desalting column containing HSA and possible ligand complexed to HSA were collected and analysed by reverse phase chromatography (RPC) on HISEP 4.6/50 (SUPELCO, U.S.A. ) .
  • the result from the RPC step may be influenced by factors such as variation in ligand concentrations in the original ligand sample and differences in extinction coefficient for different ligands.
  • Instrumentation Mixing step GILSON 215 LIQUID HANDLER with a dilutor equipped with RACK 205 for deep well microtiter plates.
  • FPLC System equipped with a HITRAP desalting column (SEPHADEX G25) (PHARMACIA BIOTECH AB, Uppsala) .
  • Sample dilution buffer and buffer A in FPLC PBS (0.05 M Phosphate, 0.15 M NaCl, pH 7.0).
  • Instant buffer for gel filtration MIKROKEMI AB, Uppsala, Sweden
  • Buffer B in FPLC Buffer A + 20 % (volume) acetonitrile . Buffer A was used for the gel filtration step and buffer B was used to regenerate the HITRAP column.
  • a screening library (Screening Library 1) was set up in order to screen for ligands that have affinity for IgG. No efficient IgG binding ligands were found. Since the library was at hand it was also checked for albumin binders.
  • Screening Library 1 was constructed from four different oxazolones :
  • the products in the library array were not further purified. Final yields were typically around 80%.
  • the crude products (ligand samples) thus sometimes consisted of a mixture of final and/or intermediate products and/or starting materials.
  • Reference Compound 1 is compound 23 in table 4.
  • the library members that were positive for binding to HSA were also checked for binding to human IgG, lysozyme and human insulin. Directed libraries and sublibraries were then constructed in order to map the Reference Compound 1-motif.
  • Compounds containing handles and attachment points for carriers were synthesized based on similar conditions to those used for the synthesis of the original library. Examples - Synthesis.
  • the particular ligand sample containing Reference Compound 1 was obtained by reaction of 3- (2-thienyl) -oxazolone with N-methyl-indole-3-aldehyde followed by subsequent ring- opening with ephedrine.
  • HSA human serum albumin
  • ligand sample contained at least four different compounds, one of which showed reactivity towards HSA.
  • the ligand sample as such was therefore subjected to preparative RPC and the four compounds were isolated and examined by mass spectrometry . It was determined that the molecular weight of the compound binding to HSA had a molecular weight of 473. In separate experiments two compounds with Mw 473, derivable from the reaction mixture and having NMR spectra suggesting they were the E and Z isomer, respectively were studied. Only Reference Compound 1 was active in binding to HSA. The results suggested that Z isomer was active in binding to albumin. No conclusive results have so far been obtained for the E-isomer.
  • [TL]t [TL(i; + tTL(2)] -kd ⁇ ss2*t
  • TL(1) and TL(2) denote the two types of complexes with the apparent dissociation rate constants kdissl and kdiss2, respectively, and t denotes the time from start of dissociation.
  • AUmin stands for the integrated peak area in those chromatograms that were recorded in the kinetic study (adsorbance units on the y-axis and minutes on the x-axis).
  • Areal and Area2 reflect the amount of ligand bound to the respective sites after 10.8 seconds (tO) of dissociation. By extrapolation to zero time the complex stoichiometry (at saturation) in the incubation mixture can be estimated. Standard curves for HSA and ligand were constructed and used to calculate the molar ratio which was found to be close to 2:1 (ligands/HSA) .
  • Reference Library AN1001 described in WO-A-9622529 was used as a reference library. It is an array based on oxazolones and contains 8000 compounds. It is a general library having members represented by formula II with known pharmacophore structures, usually aromatics, as groups A, B and L-G. Due to difficulties in solubilizing many of the members, it was never completely screened for albumin binders. The library was only used as a source for selecting interesting structures to be tested for binding to serum albumin.
  • the main objective of the synthetic design-work around the aromatic ring in the starting oxazolone (A-group) was to introduce a handle for attachment of the albumin ligand to a matrix.
  • A-group analogues see Examples - Synthesis.
  • L-G part in particular the ephedrine part, was important for high activity and selectivity for serum albumin.
  • Low binding activity could be obtained for other groups, primarily those originating from oxazolone ring opening with hydrophobic amines (R-NH 2 where R may be an hydrocarbyl group, such as aryl or alkyl group) . It is likely that this effect is retained even if the hydrocarbyl group has one or more smaller hydrophilic groups that do not completely overcome the hydrophobicity. Only ligands with L-G- parts deriving from ephedrine were therefore selected, when ligands from the reference library were selected for testing.
  • Reference library Tested compounds that have affinity to serum albumin
  • A 3-methoxy phenyl: 2,4-difluoro phenyl, 2-fluoro phenyl, 3-fluoro phenyl, 4-trifluoromethyl phenyl, 2-methyl phenyl, 3-pyridyl, 2-pyridyl.
  • A 2-naphthyl: 2,4-difluoro phenyl, 3-fluoro phenyl,
  • A 4-fluoro phenyl, 2-methyl phenyl.
  • A 2-thienyl: 3-fluoro phenyl, 4-fluoro phenyl, 1- naphthyl .
  • A 4-trifluoromethyl phenyl: 2,4-difluoro phenyl, 3- fluoro phenyl, 4-fluoro phenyl, 2-methyl phenyl,
  • A 2,4-dichloro phenyl: 2,4-difluoro phenyl, 2-fluoro phenyl, 2-trifluoromethyl phenyl, 3- trifluoromethyl phenyl, 2-methyl phenyl, 4- methoxy-phenyl, 4-phenyl phenyl, 1-naphthyl, 3,5- difluoro phenyl, 4-pyridyl, 3-quinolyl.
  • A 4-methyl phenyl: 2-fluoro phenyl, 2-methyl phenyl, 4-methioxy phenyl, 3,5-difluoro phenyl ⁇
  • A 3-methyl phenyl: 3-fluoro phenyl, 4-fluoro phenyl,
  • the characterization was performed on a JEOL ECLIPSE- 270MHz NMR. The samples were run in 5mm: s probes and the substances were dissolved in CDC1 3 or DMSO- 6 . TMS was used as an internal standard. TLC was run on MERCK KIESELGEL F 254 and was eluted with ethylacetate and then developed under UV-light (254 nm) . HPLC was performed on a SMART System on a SUPELCO HISEP column.
  • 2-Phenyloxazolone 2.5g (16mmol) was dissolved together with 2.42g (l ⁇ mmol) 1-naphthaldehyde in 15ml toluene in a screw- cap tube.
  • Triethylamine (1.0ml) was added and the closed tube placed on a heating block at 70°C over night (17h) .
  • the solvent was evaporated with heat and nitrogen and the reaction mixture was dissolved in hot ethyl acetate and a few drops of methanol and then cooled.
  • the crystals that grew from the solution were characterized to be the product by 1 H NMR.
  • the oxazolone is mixed with the amine and the solvent in a screw-cap tube.
  • the tube is placed on a heating block over night (18h) and then the solvent is evaporated with heat and/or nitrogen.
  • the synthesized products were not purified further, but used as they were.
  • the raw products were analyzed with HPLC, TLC and some of them with H NMR and ESMS.
  • the amines used are provided above, under the heading "Variations in the L-G-part".
  • the solvent, temperature and addition of triethyl amine are given in Tables 4-5.
  • A 2- (4-nitro-phenyl) oxazolones. This compound was prepared by acetic anhydride cyclization of 4-nitrohippuric acid.
  • Bl Introduction of l-methylindol-3-yl as ring system B and of structure -L-G by oxazolone ring opening with (-)-(lR, 2S)- ephedrine . These two steps were carried out as described above for other oxazolones, aldehydes and amines, the aldehyde now being l-methylindol-3-aldehyde .
  • the compound obtained in Example 3B1 was reduced with SnCl2.
  • Example 3B2 SnCl2 reduction of the ring-opened product of Example 3B2.
  • the compound obtained in Example 3B2 was reduced with SnCl2. Al .3.
  • the compound obtained in Example 3B3 was reduced with SnCl2.
  • the compound obtained in Example 3B1 was reduced with H 2 on Pd/C.
  • Example 4A1.1 Bl.Acylation of an 4-amino phenyl group in part A.
  • the product from Example 4A1.1 was acylated with acetic acid anhydride.
  • EAH SEPHAROSE 4B epoxy activated agarose that has been reacted with 1-6-diamino-hexane
  • ECH SEPHAROSE epoxy activated agarose that has been reacted with 1-6-diamino-hexane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procédé de liaison d'albumine consiste à mettre en contact un liquide aqueux contenant une albumine avec un composé de liaison d'albumine sélectionné parmi des composés de liaison d'albumine contenant le squelette -CO-NH-C(=C-)-CO-, et des conjugués qui sont capables de lier l'albumine et qui comprennent le squelette -CO-NH-C(=C-)-CO-. On décrit également un composé d'albumine qui a été produit au moyen du changement de la structure du liant d'albumine comportant le squelette -CO-NH-C(=C-)-CO-.
EP98965360A 1997-12-31 1998-12-30 Procede de liaison d'albumine et systeme destine a etre utilise dans ledit procede Withdrawn EP1044214A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/001,940 US5994507A (en) 1997-12-31 1997-12-31 Method for binding albumin and means to be used in the method
US1940 1997-12-31
SE9800879 1998-03-17
SE9800879A SE9800879D0 (sv) 1998-03-17 1998-03-17 A method for binding albumin and the novel means to be used in the method
PCT/SE1998/002468 WO1999033860A1 (fr) 1997-12-31 1998-12-30 Procede de liaison d'albumine et systeme destine a etre utilise dans ledit procede

Publications (1)

Publication Number Publication Date
EP1044214A1 true EP1044214A1 (fr) 2000-10-18

Family

ID=26663240

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98965360A Withdrawn EP1044214A1 (fr) 1997-12-31 1998-12-30 Procede de liaison d'albumine et systeme destine a etre utilise dans ledit procede

Country Status (5)

Country Link
EP (1) EP1044214A1 (fr)
JP (1) JP2001527090A (fr)
AU (1) AU2083499A (fr)
CA (1) CA2316766A1 (fr)
WO (1) WO1999033860A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9804465D0 (sv) * 1998-12-22 1998-12-22 Amersham Pharm Biotech Ab A method for the removal/purification of serum albumins and means for use in the method
US8247235B2 (en) 2007-06-08 2012-08-21 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
JP5765936B2 (ja) * 2007-06-08 2015-08-19 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド 差異荷電粒子移動度によるリポ蛋白質の分析
US9354200B1 (en) 2008-08-07 2016-05-31 Quest Diagnostics Investments Incorporated Detection apparatus for differential-charged particle mobility analyzer
US9250211B2 (en) 2010-12-30 2016-02-02 Quest Diagnostics Investments Incorporated Magnetic separation of lipoproteins using dextran sulfate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018972A1 (fr) * 1994-01-05 1995-07-13 Arqule, Inc. Production modulaire systematique de molecules a base d'aminimide et d'oxazolone ayant des proprietes choisies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663306A (en) * 1984-08-09 1997-09-02 Chiron Corporation Method of conjugating an activated ester to an amine-containing biological material
GB9414651D0 (en) * 1994-07-20 1994-09-07 Gene Pharming Europ Bv Separation of human serum albumin
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018972A1 (fr) * 1994-01-05 1995-07-13 Arqule, Inc. Production modulaire systematique de molecules a base d'aminimide et d'oxazolone ayant des proprietes choisies

Also Published As

Publication number Publication date
CA2316766A1 (fr) 1999-07-08
AU2083499A (en) 1999-07-19
JP2001527090A (ja) 2001-12-25
WO1999033860A1 (fr) 1999-07-08

Similar Documents

Publication Publication Date Title
JP4127568B2 (ja) クロマトグラフ用樹脂およびその使用方法
JPH11512442A (ja) 新規な親和性リガンド類およびそれらの用途
EP0199222A2 (fr) Garnissage chromatographique à base de polyéthylénimine acylé lié
BRPI0518216B1 (pt) ligante de cromatografia, métodos de preparação de uma matriz de separação, e de separação de um ou mais anticorpos de um ou mais outros compostos em uma amostra líquida, matriz de separação, e, coluna de cromatografia descartável.
KR910005189B1 (ko) 아실화 폴리에틸렌이민 결합상 실리카 생성물의 술폰산 유도체
US5994507A (en) Method for binding albumin and means to be used in the method
WO1999033860A1 (fr) Procede de liaison d'albumine et systeme destine a etre utilise dans ledit procede
PT95468B (pt) Processo para a preparacao de um meio contendo ligando para a separacao cromatografica apropriado para isolar moleculas sinteticas ou naturais de uma mistura fluida
CA2005917A1 (fr) Methode pour activer des vehicules polymeriques; compositions preparees a partir de ces vehicules, utiles en chromatographie d'affinite
US20050080068A1 (en) Cucurbit [n] uril compounds and analogs, and methods of making and using the same
CN1329410C (zh) 使用具有催化性能的咪唑(如组氨酸)官能团催化剂稳定的过渡配合物进行酰基转移
US6437167B1 (en) Chiral stationary phases for enantiomers separation and their preparation
JP4653079B2 (ja) 精製手段
US20050282294A1 (en) Affinity supports with immobilised protein A
CA2607851C (fr) Adsorbants d'affinite pour le plasminogene
KR20250161588A (ko) 광전환 화합물 및 친화성 리간드, 및 친화성 매트릭스의 광학적 제어를 위한 이들의 용도
JP4660472B2 (ja) アフィニティリガンドの製造法
JP2603150B2 (ja) クロマトグラフィー用の第四級化されたｐｅｉシリカ固体担体
US7205401B2 (en) Compositions and methods for separating amines and amino acids from their counter-enantiomers
US20050043522A1 (en) Separation method
CN101939642B (zh) 用于色谱法的旋光异构体分离剂及其制备方法
JP2012533728A (ja) 血清バイオマーカー分析用ヒドロゲル粒子中のベイト化学物質
US20060199950A1 (en) Preparation of a metal chelating separation medium
JPH03147800A (ja) 核酸固相化アンカー及びその調整方法
JP2005535567A (ja) 天然物精製のための高分子担持試薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010619

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMERSHAM BIOSCIENCES AB

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020528